WallStSmart
NAUT

Nautilus Biotechnology Inc

NASDAQ: NAUT · HEALTHCARE · BIOTECHNOLOGY

$2.93
-10.82% today

Updated 2026-06-05

Market cap
$347.56M
P/E ratio
P/S ratio
EPS (TTM)
$-0.46
Dividend yield
52W range
$1 – $4
Volume
0.4M

Nautilus Biotechnology Inc (NAUT) Financial statements

SEC filings — annual and quarterly data.

Balance sheet — annual

Item20182019202020212022202320242025
Total assets$145.82M$18.54M$85.01M$398.45M$350.05M$305.56M$242.74M$191.11M
Cash & equivalents$1.20M$595000.00$36.61M$185.62M$114.52M$19.40M$27.65M$12.39M
Current assets$1.33M$16.96M$77.66M$349.22M$187.21M$176.84M$132.83M$105.96M
Total liabilities$140.82M$490000.00$114.73M$34.87M$35.13M$40.21M$34.01M$34.14M
Current liabilities$5000.00$490000.00$3.02M$5.81M$6.79M$9.12M$7.63M$7.95M
Long-term debt
Shareholder equity$5.00M$18.05M$-29.72M$363.58M$314.92M$265.35M$208.73M$156.97M
Retained earnings$626600.00$-14.71M$-30.32M$-80.64M$-138.56M$-202.24M$-273.02M$-332.02M
Accounts receivable
Inventory
Goodwill

Frequently asked questions

How much free cash flow does NAUT generate?

NAUT produced $-51.97M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is NAUT's balance sheet healthy?

NAUT holds $12.39M in cash and equivalents against — in long-term debt, on $156.97M of shareholder equity. That debt is best read against the cash flow the business throws off each year.